^
Association details:
| Biomarker: | TROP2 overexpression |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | sacituzumab tirumotecan (MK-2870) (Topoisomerase I inhibitor, TROP-2-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Updated efficacy and safety of SKB264 (MK-2870) for previously treated metastatic triple negative breast cancer (mTNBC) in Phase 2 study
Published date:
12/02/2023
Excerpt:
In the subset of pts with high TROP2 expression (H-score>200, N=32), ORR was 53.1% (including 3 complete response), mDoR was 11.1 mo (range, 3.7 to 22.1+), mPFS was 5.8 mo (95% Cl: 3.7,13.3), mOS was not reached (95% Cl: 9.7, NE), while 12-mo and 24-mo OS rates were 65.3% and 57.3%, respectively….The updated data continues to demonstrate that pts with heavily pretreated mTNBC could achieve durable response and a trend of long-term OS benefit from SKB264 treatment, along with a manageable safety profile. Higher response rate was seen in mTNBC pts with high TROP2 expression.
Source:
Title:
OT1-03-02 Efficacy and safety of SKB264 for previously treated metastatic triple negative breast cancer in Phase 2 study
Published date:
11/22/2022
Excerpt:
The cORR was 55% (16/29) in the subset of patients with high TROP2 expression….Median PFS was 5.7 months (95% Cl: 3.9, 7.6)….SKB264 demonstrates a manageable safety profile and promising antitumor activity in pts with heavily pretreated mTNBC.
Trial ID:
